The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFragrant Prosp. Regulatory News (FPP)

  • This share is currently suspended. It was suspended at a price of 0.516

Share Price Information for Fragrant Prosp. (FPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.516
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.516
FPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Director

29 Mar 2021 07:00

RNS Number : 7338T
Fragrant Prosperity Holdings Ltd
29 March 2021
 

29 March 2021

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN, INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. 

 

Fragrant Prosperity Holdings Limited

("FPP" or the "Company")

Appointment of Director

The Board of Directors of Fragrant Prosperity Holdings Limited, which is seeking an acquisition in several sectors but is currently focused on Cannabis Therapeutics, is pleased to announce the appointment of Dr. Daniel S. Reshef, MD, MPH, PhD to the Board of Directors as a non-executive director. This appointment will become effective as of March 31, 2021.

Dr. Daniel Reshef is a dual Israeli and USA Citizen, currently living in the USA, with strong ties to Israel, Israel medical research centres and a vast array of relationships in the global pharmaceutical sector.

Dr Reshef's extensive career with over twenty five years in drug development encompasses many facets of the Pharmaceutical sector, gained through senior management positions at leading companies such as Hoffman La Roche, Genentech, Bristol Myers Squibb, and in his current capacity as the Therapeutic Area Global Head for a major global Pharmaceutical Company. His scientific experience includes skills in regulatory, medical affairs, drug safety operations and clinical trials epidemiology with leadership experience in early drug development from phase 1 to phase IV, and in multiple therapeutic areas.

Dr. Reshef is a board-certified physician, graduate of the Hebrew University and Hadassah Medical School in Jerusalem, and has earned his MPH and PhD in Epidemiology from Johns Hopkins University.

Craig Marshak Chairman of Fragrant Prosperity commented: "I have personally known and worked with Dr. Daniel Reshef for well over 7 years, and have always been impressed with his world wide experience and skill set. I am delighted to welcome him to the Board and look forward to the additional expertise that he brings to the Company"

Current and previous Directorships within the last 5 years that Dr Reshef holds are set out below:

Current

Previous 5 years

ABTI - Alterola pharmaceuticals - Director

 

QEBR - Virtual Medical - Director, Vice Chair

 

Israel Venture Partners - Director

 

 

 

 

 

 

 

 

*Ends*

 

For more information: http://www.fragrantprosperityholdings.com/

 

Fragrant Prosperity Holdings Limited

 

Simon Retter/Craig Marshak

+44 (0) 20 3137 1902

Broker: Optiva Securities

Vishal Balasingham +44 (0) 20 3137 1903

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADKCBKBBKKKNB
Date   Source Headline
28th Mar 20247:01 amRNSFinal Results
22nd Nov 20233:00 pmRNSStatement re. Suspension
23rd Mar 202311:27 amRNSStatement re. Suspension
16th Mar 20237:01 amRNSHolding(s) in Company
16th Mar 20237:00 amRNSHolding(s) in Company
13th Mar 20237:00 amRNSHolding(s) in Company
10th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 20232:48 pmRNSHolding(s) in Company
8th Mar 20237:00 amRNSHolding(s) in Company
6th Mar 20237:00 amRNSHolding(s) in Company
3rd Mar 20237:00 amRNSHolding(s) in Company
28th Feb 20233:17 pmRNSHolding(s) in Company
2nd Feb 20232:30 pmRNSHolding(s) in Company
26th Jan 20238:21 amRNSHolding(s) in Company
23rd Jan 20232:12 pmRNSHolding(s) in Company
29th Dec 20224:49 pmRNSHalf-year Report
30th Sep 20221:39 pmRNSAnnual Financial Report
3rd May 202212:55 pmRNSHolding(s) in Company
3rd May 202211:19 amRNSHolding(s) in Company
3rd May 202211:00 amRNSHolding(s) in Company
3rd May 202210:59 amRNSHolding(s) in Company
5th Apr 20222:39 pmRNSHolding(s) in Company
25th Mar 20224:22 pmRNSHolding(s) in Company
25th Mar 202212:55 pmRNSHolding(s) in Company
25th Mar 20227:00 amRNSHolding(s) in Company
24th Mar 20227:01 amRNSStmnt re Share Price Movement
24th Mar 20227:00 amRNSHolding(s) in Company
24th Mar 20227:00 amRNSHolding(s) in Company
23rd Mar 20221:38 pmRNSHolding(s) in Company
23rd Mar 20229:05 amRNSSecond Price Monitoring Extn
23rd Mar 20229:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSHolding(s) in Company
11th Mar 20224:37 pmRNSHolding(s) in Company
9th Mar 20222:06 pmRNSSecond Price Monitoring Extn
9th Mar 20222:00 pmRNSPrice Monitoring Extension
9th Mar 20229:05 amRNSSecond Price Monitoring Extn
9th Mar 20229:00 amRNSPrice Monitoring Extension
8th Mar 20224:23 pmRNSRestoration of Listing
8th Mar 202211:55 amRNSUpdate on Intended Acquisition
1st Feb 20227:00 amRNSHalf-year Report
13th Jan 202212:21 pmRNSResult of AGM
16th Dec 20217:00 amRNSNotice of AGM
7th Dec 20212:40 pmRNSCiiTECH transaction and LR5 notification
7th Dec 20217:00 amRNSIssue of Debt
10th Nov 20212:20 pmRNSChange of Director
30th Sep 20217:00 amRNSAnnual Financial Report
29th Jul 20214:48 pmRNSRepayment & Issue of Convertible Loan Notes
6th Jul 20218:04 amRNSUpdate on Intended Acquisition
24th May 20217:35 amRNSIntended Acquisition and Suspension of Listing
24th May 20217:30 amRNSSuspension - Fragrant Prosperity Holdings Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.